Edition:
India

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

0.89USD
18 Sep 2020
Change (% chg)

$0.08 (+9.88%)
Prev Close
$0.81
Open
$0.80
Day's High
$0.90
Day's Low
$0.80
Volume
102,603
Avg. Vol
354,941
52-wk High
$1.97
52-wk Low
$0.32

Latest Key Developments (Source: Significant Developments)

Moleculin Biotech Files For Mixed Shelf Of Upto $75 Mln - SEC Filing
Saturday, 18 Jan 2020 

Jan 17 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING.  Full Article

Moleculin Biotech Inc Q2 Loss Per Share $0.03
Saturday, 17 Aug 2019 

Aug 16 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH INC - QTRLY LOSS PER SHARE $0.03.MOLECULIN BIOTECH INC - FINISHED Q2 WITH CASH OF APPROXIMATELY $18.7 MILLION AND NO DEBT.MOLECULIN BIOTECH- BELIEVE EXISTING CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS WELL INTO 2020.  Full Article

Moleculin Announces $15.0 Mln Registered Direct Offering
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES $15.0 MILLION REGISTERED DIRECT OFFERING.MOLECULIN BIOTECH - ENTERED AGREEMENTS WITH INSTITUTIONAL INVESTORS TO BUY 9.4 MILLION UNITS AT $1.60/UNIT IN REGISTERED DIRECT OFFERING.MOLECULIN BIOTECH INC - EACH UNIT IS COMPRISED OF ONE SHARE OF COMMON STOCK AND 0.5 OF A WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK..MOLECULIN BIOTECH INC - EACH WARRANT WILL HAVE AN EXERCISE PRICE OF $1.75 PER SHARE AND IS EXERCISABLE IMMEDIATELY..MOLECULIN BIOTECH - INTENDS TO USE NET PROCEEDS TO FUND PLANNED CLINICAL TRIALS, PRECLINICAL PROGRAMS, FOR OTHER RESEARCH AND DEVELOPMENT ACTIVITIES.  Full Article

Moleculin Biotech Announces FDA Filing For Orphan Drug Designation
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES FDA FILING FOR ORPHAN DRUG DESIGNATION FOR GLIOBLASTOMA DRUG.  Full Article

Moleculin announces new data further supporting its lead drug for treating pancreatic cancer
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES NEW DATA FURTHER SUPPORTING ITS LEAD DRUG FOR TREATING PANCREATIC CANCER.MOLECULIN BIOTECH INC - DATA CONFIRMED THAT IMMUNO-STIMULATING STAT3 INHIBITOR ACHIEVES DISPROPORTIONATELY HIGH ACCUMULATION IN PANCREAS.MOLECULIN BIOTECH - TARGETED TO FILE INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH FDA IN 2019.  Full Article

Moleculin Biotech Inc Quarterly Loss Per Share $0.08
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH, INC. REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2018.MOLECULIN BIOTECH INC QUARTERLY LOSS PER SHARE $0.08.  Full Article